Healthcare Business

graph

Can Gilead Shares Still Really Rise to $150?

Gilead Sciences Inc. (NASDAQ: GILD) recently saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon. This independent analyst ...
Read Full Story »
IPO

Viamet Pharma Announces Potential Pricing for IPO

Viamet Pharmaceuticals has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 5.7 million ...
Read Full Story »
Hepatitis Virus

3 Underfollowed Infectious Disease Stocks That Deserve More Attention

Infectious diseases always have been a hot topic in biotech, but over the past half decade, with the outbreak of Ebola in Africa and more recently the Zika virus in ...
Read Full Story »
Pfizer

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

When Pfizer Inc. (NYSE: PFE) reported first-quarter 2016 results before markets opened Tuesday, it posted adjusted diluted earnings per share (EPS) of $0.67 and revenues of $13 billion. In the ...
Read Full Story »
biotech word cloud

Can Shares of Aeglea BioTherapeutics Really More Than Double?

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) has only been public for a few weeks, but the analysts from its underwriting syndicate have issued massive upside calls. The driving force behind Aeglea ...
Read Full Story »
coins

What to Expect From Pfizer Earnings

Pfizer Inc. (NYSE: PFE) is scheduled to report its first-quarter financial results before the markets open on Tuesday. Thomson Reuters has consensus estimates calling for $0.55 in earnings per share ...
Read Full Story »
IPO

Cotiviti Holdings Files for IPO

Cotiviti Holdings has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
Pills and tablets

How Analysts View Vertex After Earnings

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) reported its first-quarter financial results on Wednesday after the markets closed. Despite making some solid gains on Thursday after a mixed earnings report, the stock ...
Read Full Story »
surgery

Did Molina Healthcare’s Future Just Get Compromised?

Molina Healthcare Inc. (NYSE: MOH) to a real beating on Thursday after reporting a bad miss on first-quarter earnings. The stock was down nearly 20% on Friday after the company ...
Read Full Story »
analysis

How Analysts View Stericycle After Earnings

Stericycle Inc. (NASDAQ: SRCL) reported its first-quarter financial results after the markets closed on Thursday. Unfortunately, the results missed earnings expectations and the stock saw a new 52-week low early ...
Read Full Story »
clinical trials

Gilead Results Trip Over Both the Top and Bottom Lines

Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared ...
Read Full Story »
coins

Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance

Bristol-Myers Squibb Co. (NYSE: BMY) released its first-quarter financial results before the markets opened on Thursday. The company said it had $0.74 in earnings per share (EPS) on $4.4 billion ...
Read Full Story »
white pills

Why AbbVie Earnings Failed to Impress Investors

AbbVie Inc. (NYSE: ABBV) reported its first-quarter financial results before the markets opened on Thursday. The company said it had $1.15 in earnings per share (EPS) on $5.96 billion in ...
Read Full Story »
IPO

Intellia Therapeutics Announces Potential Pricing for IPO

Intellia Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 5 million shares ...
Read Full Story »